Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Prostate cancer

Circulating free DNA as biomarker

Nature Reviews Urology volume 14, page 390 (2017)Cite this article

Subjects

Genomic analysis of serial, circulating free DNA (cfDNA) samples in patients undergoing PARP inhibitor (PARPi) therapy can be used to predict treatment responses and monitor emergence of PARPi resistance mutations, according to a new study in Cancer Discovery.

The TOPARP-A trial had found that the PARPi olaparib had antitumour activity in men with metastatic castration-resistant prostate cancer, which was associated with mutations in homologous DNA recombination (HDR) genes. During the trial, the investigators had collected cfDNA samples to test their ability to predict response and elucidate the molecular evolution of PARPi resistance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Goodall, J. et al. Circulating free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. http://dx.doi.org/10.1158/2159-8290.CD-17-0261 (2017)

Download references

Authors
  1. Clemens Thoma
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Thoma, C. Circulating free DNA as biomarker. Nat Rev Urol 14, 390 (2017). https://doi.org/10.1038/nrurol.2017.74

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2017.74

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer